Why the study?
Does tissue-type plasminogen activator improve clinical outcomes compared to streptokinase in patients with acute myocardial infarction?
Population
Patients with acute myocardial infarction (based on the GUSTO study example)
Comparison
Tissue-type plasminogen activator vs Streptokinase
Design
Other
Authors
Loading...
Questions tPA preference over streptokinase in AMI; challenges GUSTO frequentist conclusions and guidelines.
Does tissue-type plasminogen activator improve clinical outcomes compared to streptokinase in patients with acute myocardial infarction?
Bayesian analysis provides a formal method to evaluate the probability of a clinically meaningful difference, demonstrating that the superiority of tPA over streptokinase in the GUSTO trial remains uncertain.
James M. Brophy (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: